Strategy To Tether Organometallic Ruthenium-Arene Anticancer Compounds to Recombinant Human Serum Albumin

In order to utilize macromols. for drug targeting and delivery, a strategy to tether organometallic ruthenium-arene drugs to carrier protein mols. was developed. The approach involves the design of a drug fragment capable of conjugating to linker mols. on a modified carrier protein via hydrazone bond formation. The proof-of-concept using recombinant human serum albumin is described.


Published in:
ORGANOMETALLICS, 46, 22, 9048-9050
Year:
2007
Other identifiers:
Laboratories:




 Record created 2007-12-13, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)